On that score, the company has support from many mental health advocates who argue that open access to medications saves money by reducing hospital admissions and keeping patients productive. But current or former officials in Georgia, Kentucky and Tennessee are among those who say Lilly tied the program to unrestricted access to Zyprexa and the company's other mental health drugs. Lilly's pitch in 2005 was, " 'we'll fund this program if you put our product on the preferred-drug list,' " said David Beshara, chief pharmacy officer for Tennessee Medicaid.